CureVac: The Hidden Value Of The mRNA Wallet
CureVac is a pioneering biotech company focused on mRNA drugs for oncology and vaccines. In biotech, value derives from research quality, patent strength, and clinical success probability, not current revenues. CVAC boasts over 25 years of research and nearly 1,000 mRNA patents, highlighting its intellectual property strength.
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech
CVAC jumps 41% in a month after signing a $1.25B deal to be acquired by BioNTech to accelerate mRNA therapy development.
CureVac Stock Soars on BioNTech Buyout
Biotech stock CureVac NV (NASDAQ:CVAC) was last seen up 32.2% at $5.37, after news that BioNTech (BNTX) is acquiring the company in all-stock deal worth $1.25 billion.
CureVac N.V. (CVAC) Q4 2024 Earnings Call Transcript
CureVac N.V. (NASDAQ:CVAC ) Q4 2024 Earnings Conference Call April 10, 2025 9:00 AM ET Company Participants Sarah Fakih - Vice President, Corporate Communications and Investor Relations Alexander Zehnder - Chief Executive Officer Myriam Mendila - Chief Scientific Officer Axel Sven Malkomes - Chief Financial Officer Conference Call Participants Alec Stranahan - Bank of America Ryan McElroy - Leerink Partners Roger Song - Jefferies Jasmine Fels - UBS Roy Buchanan - Citizens JMP Jonathan Miller - Evercore ISI Chiara Montironi - Kempen Operator Greetings.
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps
CureVac N.V. CVAC on Thursday said the European Patent Office (EPO) confirmed the validity of CureVac's European patent EP 3 708 668 B1 subject to amendments to specify the scope of protection.
European Patent Office declares CureVac mRNA patent valid
The European Patent Office declared a patent owned by CureVac , valid, after a challenge from drugmaker BioNTech , the company said on Thursday.
CureVac: Latest GBM Data Bodes Well For Next Program Check Point
CureVac N.V.'s CVGBM vaccine showed positive safety and immunogenicity data in Part A of its phase 1 study for resected glioblastoma, with no dose-limiting toxicities. Key catalysts include Part B CVGBM resectable GBM data release in 2nd half of 2025 and possible phase 2 study initiation in 2nd half of 2026. The company is also developing a vaccine for squamous NSCLC, with an IND filing expected in the 1st half of 2025 and phase 1 study initiation in the 2nd half of 2025.
2 Small-Cap Stocks Set to Shine in a Bull Market
Small-cap stocks often experience outsized gains during bullish markets. Their smaller market capitalizations and growth-oriented profiles make them more sensitive to improving economic conditions, where rising investor confidence drives capital toward higher-risk, higher-reward opportunities.
Is the Options Market Predicting a Spike in CureVac (CVAC) Stock?
Investors need to pay close attention to CureVac (CVAC) stock based on the movements in the options market lately.
CureVac N.V. (CVAC) Q3 2024 Earnings Call Transcript
CureVac N.V. (NASDAQ:CVAC ) Q3 2024 Earnings Conference Call November 12, 2024 9:00 AM ET Company Participants Sarah Fakih - Vice President of Corporate Communications and Investor Relations Alexander Zehnder - Chief Executive Officer Axel Malkomes - Chief Financial Officer Myriam Mendila - Chief Development Officer Rudiger Wolff - Senior Vice President of Finance Conference Call Participants Charlie Yang - Bank of America Merrill Lynch CJ Yeh - Leerink Partners Roy Buchanan - Citizens JMP Operator Greetings and welcome to the CureVac Financial Results and Business Update for the Third Quarter and First Nine Months of 2024 Conference Call.
CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the third quarter and first nine months 2024 on Tuesday, November 12, 2024.
CureVac to Present at the 12th International mRNA Health Conference
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that new and updated data will be shared in two oral presentations and four posters at the 12th International mRNA Health Conference, taking place in Boston, Massachusetts, November 12-14, 2024.
